PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15564778-0	2004	Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma.	Bleomycin	69-78	interleukin 13	Mus musculus	16-30	
15564778-6	2004	RESULTS: RT-PCR showed that both IL-4 and IL-13 mRNA levels in skin lesions were increased and peaked after 4 weeks of bleomycin treatment.	Bleomycin	119-128	interleukin 4	Mus musculus	33-37	
15564778-6	2004	RESULTS: RT-PCR showed that both IL-4 and IL-13 mRNA levels in skin lesions were increased and peaked after 4 weeks of bleomycin treatment.	Bleomycin	119-128	interleukin 13	Mus musculus	42-47	
15564778-10	2004	In skin lesions, IL-13 receptor (IL-13R) alpha2 expression was augmented mainly in the infiltrating mononuclear cells after 4 weeks of bleomycin exposure.	Bleomycin	135-144	interleukin 13	Mus musculus	17-22	
15564778-10	2004	In skin lesions, IL-13 receptor (IL-13R) alpha2 expression was augmented mainly in the infiltrating mononuclear cells after 4 weeks of bleomycin exposure.	Bleomycin	135-144	interleukin 13 receptor, alpha 2	Mus musculus	33-47	
15564778-12	2004	On the contrary, mRNA expression of IL-13Ralpha1 and IL- 13Ralpha2 was significantly altered in the cultured fibroblasts derived from bleomycin-treated skin.	Bleomycin	134-143	interleukin 13 receptor, alpha 1	Mus musculus	36-48	
15564778-12	2004	On the contrary, mRNA expression of IL-13Ralpha1 and IL- 13Ralpha2 was significantly altered in the cultured fibroblasts derived from bleomycin-treated skin.	Bleomycin	134-143	interleukin 13 receptor, alpha 2	Mus musculus	53-66	
15564778-13	2004	CONCLUSION: These data demonstrate that in skin lesions levels of IL-13 as well as its receptor increase in parallel with DSc progression, suggesting that IL-13 promotes the progression of cutaneous fibrosis/sclerosis in the murine model of bleomycin-induced scleroderma.	Bleomycin	241-250	interleukin 13	Mus musculus	66-71	
15564778-13	2004	CONCLUSION: These data demonstrate that in skin lesions levels of IL-13 as well as its receptor increase in parallel with DSc progression, suggesting that IL-13 promotes the progression of cutaneous fibrosis/sclerosis in the murine model of bleomycin-induced scleroderma.	Bleomycin	241-250	interleukin 13	Mus musculus	155-160